|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft显示文摘 | Teresa M. Antonini Valerie Furlan Elina Teicher Stephanie Haim-Boukobza Mylene Sebagh Audrey Coilly Laurence Bonhomme-Faivre Gilles Peytavin Anne-Marie Roque-Afonso Daniel Vittecoq Didier Samuel Anne-Marie Taburet Jean-Charles Duclos-Vallée | 2013 | AIDS2013，，16： | 2 |
| 2 | Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy 显示文摘 | Bernard L Peytavin G Vuagnat A et at | 1998 | Lancet1998，352，9142： | 1 |
| 3 | GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy显示文摘 | BOSSI P PEYTAVIN G AIT-MOHAND H | 2004 | HIV Med2004，5，5： | 1 |
| 4 | Relationship between levels of indinavir in hair and virologic response to highly active an- tiretroviral therapy显示文摘 | Bernard L Vuagnat A Peytavin G | 2002 | Ann Intern Med2002，137，8： | 1 |
| 5 | Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients显示文摘AIM To describe factors associated with treatment failure and frequency of resistance-associated substitutions(RAS).METHODS Human immunodeficiency virus(HIV)/hepatitis C virus(HCV) coinfected patients starting a first direct-acting antiviral(DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as:(1) non-response [HCV-RNA remained detectable during treatment, at end of treatment(EOT)]; and(2) relapse(HCVRNA suppressed at EOT but detectable thereafter). Sequencing analysis was performed to describe prevalence of drug class-specific RAS. Factors associated with failure were determined using logistic regression models.RESULTS Among 559 patients, 77% had suppressed plasma HIV-RNA < 50 copies/mL at DAA treatment initiation, 41% were cirrhotic, and 68% were HCV treatmentexperienced. Virological treatment failures occurred in 22 patients and were mainly relapses(17, 77%) then undefined failures(3, 14%) and non-responses(2, 9%). Mean treatment duration was 16 wk overall. Posttreatment NS3, NS5 A or NS5 B RAS were detected in 10/14 patients with samples available for sequencing analysis. After adjustment for age, sex, ribavirin use, HCV genotype and treatment duration, low platelet count was the only factor significantly associated with a higher risk of failure(OR: 6.5; 95%CI: 1.8-22.6). CONCLUSION Only 3.9% HIV-HCV coinfected patients failed DAA regimens and RAS were found in 70% of those failing. Low platelet count was independently associated with virological failure. | Dominique Salmon Pascale Trimoulet Camille Gilbert Caroline Solas Eva Lafourcade Julie Chas Lionel Piroth Karine Lacombe Christine Katlama Gilles Peytavin Hugues Aumaitre Laurent Alric Franoois Boué Philippe Morlat Isabelle Poizot-Martin Eric Billaud Eric Rosenthal Alissa Naqvi Patrick Miailhes Firouzé Bani-Sadr Laure Esterle Patrizia Carrieri Franoois Dabis Philippe Sogni Linda Wittkop 无 | 2018 | World Journal of Hepatology2018，10，11： | 1 |
| 6 | Adherence to antiretroviral therapy assessed by drug level monitoring and selfreport in Cameroon显示文摘 | KOUANFACK C LAURENT C PEYTAVIN G | 2008 | J Acquir Immune Defic Syndr2008，48，2： | 1 |
| 7 | Value of patient se- lf-report and plasma human immunodeficiency virus pro- tease inhibitor level as markers of adherence to antiretrovi- ral therapy:relationship to virologic response显示文摘 | Duong M Piroth L Peytavin G | 2001 | Clin In- fect Dis2001，33，3： | 1 |
| 8 | Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women 显示文摘 | MANDELBORT L PEYTAVIN G FIRTION G | 2001 | Am J Obstet Gynecol2001，184，： | 1 |
| 9 | Simplex and multiplex real-time PCR assays for the dctection of flagellar (H-antigen) fliC alleles and intimin (eae) variants associated with enterohaemorrhagic Escherichia coli(EHEC) serotypes O26:H 11,O103:H2,O 111:H8,O145:H28 and O157:H7显示文摘 | Madic J Peytavin de Garam C Vingadassalon N | | 0，，05： | 1 |
| 10 | Evolution of human im- munodeficiency virus type 1 (HIV-1) resistance mutations in non- nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1- infected patients switched to antiretroviral therapy without NNR- TIs 显示文摘 | Joly V Descamps D Peytavin G | 2004 | Antimicrob Agents Chemother2004，48，1： | 1 |
| 11 | Placental transfer oflopinavir/ritonavir in the ex vivo human cotyledon perfusionmodel显示文摘 | Gavard L Gil S Peytavin G | 2006 | Am J Obstet Gynecol2006，195，： | 1 |
| 12 | Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy:relationship to virologic response显示文摘 | Duong M Piroth L Peytavin G | 2001 | Clin Infect Dis2001，33，3： | 1 |
| 13 | Value of patientself re-port and plasma human immunodeficiency virus protease in-hibitor level as markers of adherence to antiretroviral thera-py :relationship to virologic response 显示文摘 | Duong M Piroth L Peytavin G | 2001 | Clin Infect Dis2001，33，3： | 1 |
| 14 | Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial)显示文摘 | Molina JM Peytavin G Perusat S | 2004 | HIV Medicine2004，5，2： | 1 |
| 15 | Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model 显示文摘 | Forestier F de Renty P Peytavin G Dohin E Farinotti R Mandelbrot L | 2001 | Am J Obstet Gynecol2001，185，1： | 1 |
| 16 | Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model 显示文摘 | Gavard L Gil S Peytavin G Ceccaldi PF Ferreira C Farinotti R | 2006 | Am J Obstet Gynecol2006，195，1： | 1 |
| 17 | Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model显示文摘 | Gavard L Gil S Peytavin G | 2006 | Am J Obstet Gynecol2006，195，： | 1 |
| 18 | Evolution of human im muno- deficiency virus type 1 (HIV1) resistance mutations in nonnucleoside reverse transcriptase inhihitors (NNRTIs) in HIV 1-infected patients switched to antiretroviral therapy with- out NNRTIs显示文摘 | Joly V Descamps D Peytavin G | 2004 | Antimicrob Agents Chemother2004，48，1： | 1 |
| 19 | Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers显示文摘 | Peytavin G Gautran C Otoul C | 2005 | Eur J Clin Pharmacol2005，61，4： | 1 |
| 20 | Maternalfetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women显示文摘 | MANDELBROT L PEYTAVIN G FIRTION G | 2001 | Am J Obstet Gynecol2001，184，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员